FDA Approves Sogroya (somapacitan-beco) a Once-Weekly Treatment for Adult Growth Hormone Deficiency

Plainsboro, NJ, Aug 28, 2020 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for Sogroya (somapacitan-beco) injection 10 mg/ 1.5 mL (6.7 mg/mL) for the replacement of...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news